Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | JAK2 | O60674 | 7/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | PRKX | P51817 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816598 | 1.00 | CDK19 (0.58) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14662261 | 0.91 | CDK19 (0.67) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14670406 | 0.91 | CDK19 (0.67) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14662070 | 0.91 | CDK19 (0.67) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14670415 | 0.90 | JAK2 (0.53) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14663651 | 0.90 | JAK3 (0.47) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14663649 | 0.90 | JAK3 (0.47) | CDK19ALKJAK2CDC7DAPK3 | |
| SCHEMBL14663711 | 0.90 | JAK3 (0.50) | CDK19ALKJAK2JAK3JAK1 | |
| SCHEMBL14663709 | 0.90 | JAK3 (0.50) | CDK19ALKJAK2JAK3JAK1 | |
| SCHEMBL15815983 | 0.90 | JAK2 (0.53) | CDK19ALKJAK2CDC7DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | claimed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2736901-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | CDK19 188/4885ALK 2106/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.